# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

A. 510(k) Number: k093737   
B. Purpose for Submission: New device   
C. Measurand: Controls for assays detecting Factor II (FII) and Factor V (FV) gene mutations   
D. Type of Test: Assayed Quality Control material   
E. Applicant: Instrumentation Laboratory Co.   
F. Proprietary and Established Names: HemosIL FII & FV DNA Control

# G. Regulatory Information:

2. Classification: Class II

3. Product code: NZB, Quality Control material, genetics, DNA

4. Panel: Immunology (82)

# H. Intended Use:

1. Intended use(s): HemosIL FII & FV DNA Control is intended for in vitro diagnostic use as a heterozygous quality control to monitor analytical performance of the extraction, amplification and detection steps of the Xpert™ HemosIL FII & FV genotyping assay on the GeneXpert $\textsuperscript { \textregistered }$ Dx System used in the detection of both the Factor II $2 0 2 1 0 \mathrm { G } { > } \mathrm { A }$ and Factor $\mathrm { ~ V ~ } 1 6 9 1 \mathrm { G } { > } \mathrm { A }$ (Leiden) mutations. For in vitro diagnostic use.   
2. Indication(s) for use: Same as Intended Use   
3. Special conditions for use statement(s): For prescription use only.   
4. Special instrument requirements: GeneXpert $\textsuperscript { \textregistered }$ Dx System (k060540)

# I. Device Description:

HemosIL FII & FV DNA Control is synthetic Factor II (FII) and Factor V (FV) DNA suspended in a non-infectious blood-like matrix. Each vial includes normal and mutated Factor II and Factor V DNA sequences as follows:

Table 1. No. of bases flanking each mutation site for both FII and FV   

<table><tr><td rowspan=1 colspan=1>Construct</td><td rowspan=1 colspan=1>5&#x27;</td><td rowspan=1 colspan=1>3&#x27;</td></tr><tr><td rowspan=1 colspan=1>FII wild type</td><td rowspan=1 colspan=1>511</td><td rowspan=1 colspan=1>125</td></tr><tr><td rowspan=1 colspan=1>FII mutant</td><td rowspan=1 colspan=1>511</td><td rowspan=1 colspan=1>122</td></tr><tr><td rowspan=1 colspan=1>FV wild type</td><td rowspan=1 colspan=1>434</td><td rowspan=1 colspan=1>394</td></tr><tr><td rowspan=1 colspan=1>FV mutant</td><td rowspan=1 colspan=1>434</td><td rowspan=1 colspan=1>394</td></tr></table>

HemosIL FII & FV DNA Control is configured as a heterozygous control for both Factor I $\mathrm { I } 2 0 2 1 0 \mathrm { G } { > } \mathrm { A }$ and Factor $\mathrm { ~ V ~ } 1 6 9 1 \mathrm { G } { > } \mathrm { A }$ (Leiden) mutations. The ratio of FII and FV DNA to non-human carrier DNA is 1:186.

The quality control material is validated for use with Xpert™ HemosIL $^ \mathrm { \textregistered }$ FII & FV genotyping assay on the GeneXpert $\textsuperscript { \textregistered }$ Dx System and is processed exactly as whole blood samples during the extraction, amplification and detection steps.

# J. Substantial Equivalence Information:

1. Predicate device name(s): INTROL™ CF Panel I Control   
2. Predicate 510(k) number(s): K083171   
3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Physical Composition</td><td rowspan=1 colspan=1>Synthetic (recombinant) DNA with non-human carrier DNA, preservatives, dye andstabilizers</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Physical Format</td><td rowspan=1 colspan=1>Ready-to-use liquid</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Assay StepsMonitored</td><td rowspan=1 colspan=1>Extraction, Amplification and Detection</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>RecommendedStorage</td><td rowspan=1 colspan=1>2-8°</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Method to ValidatePresence Mutations</td><td rowspan=1 colspan=1>Bi-directional sequencing</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Directions for Use</td><td rowspan=1 colspan=1>Handle control in the same manner as thepatient sample</td><td rowspan=1 colspan=1>Same</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Gene Segment</td><td rowspan=1 colspan=1>Factor II (20210G&gt;A)Factor V (1691G&gt;A Leidenmutation)</td><td rowspan=1 colspan=1>CFTR (38 mutations; 4variants)</td></tr></table>

K. Standard/Guidance Document Referenced (if applicable): None referenced.

L. Test Principle: Not applicable.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

All testing of the HemosIL FII & Factor V Control was performed using the FDA cleared Xpert HemosIL Factor II & Factor V Assay (k082118) performed on the FDA cleared GeneXpert Dx System (k060540).

a. Precision/Reproducibility:

Repeatability: Two lots of HemosIL FII & FV DNA Control were tested in replicates of 5 using a single lot of Xpert HemosIL Factor II & Factor V Assay on the GeneXpert Dx instrument. In addition, five replicates of one Control lot were tested using a second lot of HemosIL Factor II & Factor V Assay. All genotypes were called correctly and results are summarized as follows:

<table><tr><td rowspan=1 colspan=3></td><td rowspan=1 colspan=2>FII GNormal</td><td rowspan=1 colspan=2>FII AMutant</td><td rowspan=1 colspan=2>FV GNormal</td><td rowspan=1 colspan=2>FVAMutant</td></tr><tr><td rowspan=1 colspan=1>ControlLot #</td><td rowspan=1 colspan=1>AssayLot #</td><td rowspan=1 colspan=1>Correct Results(FII Het/ FVHet)</td><td rowspan=1 colspan=1>MeanCt</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>MeanCt</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>MeanCt</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>MeanCt</td><td rowspan=1 colspan=1>SD</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>100% (5/5)</td><td rowspan=1 colspan=1>27.3</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>26.4</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>27.3</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>27.4</td><td rowspan=1 colspan=1>0.7</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>100% (5/5)</td><td rowspan=1 colspan=1>27.0</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>25.9</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>26.8</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>27.0</td><td rowspan=1 colspan=1>0.3</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100% (5/5)</td><td rowspan=1 colspan=1>25.9</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>25.4</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>26.1</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>26.2</td><td rowspan=1 colspan=1>0.4</td></tr></table>

Lot-to-Lot Variability: Three lots of HemosIL FII & FV DNA Control were tested in replicates of five using 1 lot of Xpert HemosIL Factor II & Factor V Assay on the GeneXpert Dx instrument. All genotypes were called correctly and results are summarized as follows:

<table><tr><td rowspan=1 colspan=3></td><td rowspan=1 colspan=2>FII GNormal</td><td rowspan=1 colspan=2>FII AMutant</td><td rowspan=1 colspan=2>FV GNormal</td><td rowspan=1 colspan=2>FVAMutant</td></tr><tr><td rowspan=1 colspan=1>ControlLot #</td><td rowspan=1 colspan=1>1 No. ofTests</td><td rowspan=1 colspan=1>Correct Results(FII Het/FVHet)</td><td rowspan=1 colspan=1>MeanCt</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>MeanCt</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>MeanCt</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>MeanCt</td><td rowspan=1 colspan=1>SD</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>100% (22/22)</td><td rowspan=1 colspan=1>26.4</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>25.9</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>26.8</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>27.0</td><td rowspan=1 colspan=1>0.8</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>100% (17/17)</td><td rowspan=1 colspan=1>26.4</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>25.9</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>26.7</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>27.0</td><td rowspan=1 colspan=1>0.7</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>100%b (15/15)</td><td rowspan=1 colspan=1>26.6</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>26.0</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>26.9</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>27.0</td><td rowspan=1 colspan=1>0.8</td></tr><tr><td rowspan=1 colspan=1>ALL</td><td rowspan=1 colspan=1>54</td><td rowspan=1 colspan=1>100% (54/54)</td><td rowspan=1 colspan=1>26.4</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>25.9</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>26.8</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>27.0</td><td rowspan=1 colspan=1>0.8</td></tr></table>

Reproducibility: Three lots of HemosIL FII & FV DNA Control were tested using 3 different lots of Xpert HemosIL Factor II & Factor V Assay on different GeneXpert Dx instruments at multiple sites by multiple operators. A total of 201 tests were performed. All genotypes were called correctly and results are summarized as follows:

<table><tr><td rowspan=1 colspan=3></td><td rowspan=1 colspan=2>FII GNormal</td><td rowspan=1 colspan=2>FII AMutant</td><td rowspan=1 colspan=2>FV GNormal</td><td rowspan=1 colspan=2>FVAMutant</td></tr><tr><td rowspan=1 colspan=1>Control No. ofLot #</td><td rowspan=1 colspan=1>Control No. ofTests</td><td rowspan=1 colspan=1>Correct Results(FII Het/FVHet)</td><td rowspan=1 colspan=1>MeanCt</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>MeanCt</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>MeanCt</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>MeanCt</td><td rowspan=1 colspan=1>SD</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>100% (45/45)</td><td rowspan=1 colspan=1>26.5</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>25.9</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>26.8</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>27.0</td><td rowspan=1 colspan=1>0.9</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>122</td><td rowspan=1 colspan=1>100% (122/122)</td><td rowspan=1 colspan=1>26.1</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>25.3</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>26.2</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>26.2</td><td rowspan=1 colspan=1>0.8</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>34</td><td rowspan=1 colspan=1>100% (34/34)</td><td rowspan=1 colspan=1>26.8</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>26.0</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>26.9</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>26.9</td><td rowspan=1 colspan=1>0.7</td></tr><tr><td rowspan=1 colspan=1>ALL</td><td rowspan=1 colspan=1>201</td><td rowspan=1 colspan=1>100% (201/201)</td><td rowspan=1 colspan=1>26.3</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>25.6</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>26.5</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>26.6</td><td rowspan=1 colspan=1>0.8</td></tr></table>

b. Linearity/assay reportable range:

Not applicable.

c. Traceability, Stability, Expected values (controls, calibrators, or methods): Traceability

Validation was performed by bidirectional sequencing of HemosIL FII & FV DNA Control.

Upon receipt and after opening, the material should be stored at $2 ^ { \circ } - 8 ^ { \circ } \mathrm { C }$

HemosIL FII & FV DNA Control material is shipped with a "Do not freeze" warning in the device labeling.

Unopened HemosIL FII & FV DNA Control material is stable for 18 months when stored refrigerated $( 2 ^ { \circ } - 8 ^ { \circ } \mathrm { C } )$ . Opened material returned to the refrigerator $( 2 ^ { \circ } - 8 ^ { \circ } \mathrm { C } )$ shortly after use is stable for thirty (30) days from the date of opening.

Real-Time Stability Study

Three different lots of HemosIL FII & FV DNA Control were tested at defined time intervals for up to 570 days, 565 days and 64 days, respectively, using the Xpert HemosIL Factor II & Factor V Assay. Data from this ongoing real-time stability study supports a shelf-life of 18 months.

Open-Vial Stability Study

Vials from two different lots of HemosIL FII & FV DNA Control were opened, tested in duplicate at Day 0 and stored at $2 { - } 8 ^ { \circ } \mathrm { C }$ for 34 days. Normal laboratory use was simulated over the test period by periodically warming the vials to room temperature and pipetting the control material, but then returning it to the vial. At Day 34, the open vials were tested in duplicate and the Ct (Crossing Threshold) results compared to the Ct results from time zero. The study demonstrated no loss of signal when used in Xpert HemosIL Factor II & Factor V Assay performed on the GeneXpert Dx Systemassay at the end of the test period.

Stress Testing Study

Shipping Study:

Two different lots of HemosIL FII & FV DNA Control were shipped in March via US Postal Service across the U.S. from Maine to California without ice packs. After receipt in California, the controls were left at room temperature for 3 days before being shipped back to Maine, again without ice packs. The total transit time was 13 days. The returned controls were tested using Xpert HemosIL Factor II & Factor V Assay on the GeneXpert Dx System. The data demonstrates product stability during prolonged shipping without refrigeration.

Freeze/Thaw Study: Two different lots of HemosIL FII & FV DNA Control were frozen at - $2 0 \mathrm { { ^ \circ C } }$ for 48 hours and then thawed for testing using Xpert HemosIL Factor II & Factor V Assay on the GeneXpert Dx System. The data demonstrates one freeze/thaw cycle will not degrade the product.

Expected values   
The expected results with the HemosIL FII & FV DNA Control using the FDA-cleared Xpert HemosIL FII & FV genotyping assay on the GeneXpert Dx System are heterozygous genotype for both Factor $\Pi 2 0 2 1 0 \mathrm { G } { > } \mathrm { A }$ and Factor $\mathrm { ~ V ~ } 1 6 9 1 \mathrm { G } { > } \mathrm { A }$ (Leiden) mutations.

d. Detection limit: Not applicable e. Analytical specificity: Not applicable

2. Comparison studies: a. Method comparison with predicate device: Not applicable b. Matrix comparison: Not applicable

3. Clinical studies: a. Clinical Sensitivity: Not applicable b. Clinical specificity: Not applicable c. Other clinical supportive data (when a. and b. are not applicable): Not applicable

4. Clinical cut-off: Not applicable

5. Expected values/Reference range: Not applicable

N. Proposed Labeling: The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.